fda warning letters compounded semaglutide tirzepatide september 2025 30 telehealth companies received U.S. Food and Drug Administration for falsely marketing GLP-1 products online. said these companies claimed that their products are similar to generic FDA-approved products NCL Issues a Second Alert

Description

Telehealth eliminates these interactions

Rare Side Effects : Serious allergic reactions like anaphylaxis, symptoms of which include difficulty breathing, swelling of the face and throat, wheezing, fast heartbeat, dizziness, or cold, pale skin

Common side effects are usually mild and temporary

Implications for pharma companies: Pharmas entry into the trillion-dollar club is largely driven by success in a treatment category (obesity) poised to reshape consumer health and wellness, given the massive demand for better weight loss solutions

Conversely, people who view the switch as an active choice to optimize their protocol often maintain better psychological adjustment and persistence through temporary difficulties